Last reviewed · How we verify
Gadovist®/Gadavist®
Gadovist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.
Gadovist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues. Used for Contrast enhancement for MRI of the central nervous system (brain and spinal cord), Contrast enhancement for MRI of the body (organs, tissues, and vasculature).
At a glance
| Generic name | Gadovist®/Gadavist® |
|---|---|
| Sponsor | Guerbet |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Gadovist contains gadolinium, a paramagnetic metal ion that is chelated with a ligand (gadoterate meglumine) to create a stable complex. When injected intravenously, it distributes through the body and accumulates in areas of interest, altering the magnetic properties of nearby water molecules to increase signal intensity on T1-weighted MRI images, thereby improving visualization of anatomical structures and pathology.
Approved indications
- Contrast enhancement for MRI of the central nervous system (brain and spinal cord)
- Contrast enhancement for MRI of the body (organs, tissues, and vasculature)
Common side effects
- Headache
- Dizziness
- Nausea
- Injection site reactions
- Gadolinium retention (in patients with renal impairment)
Key clinical trials
- Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection
- Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings (PHASE4)
- Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age
- Low-dose Imaging Technique (LITE) (NA)
- Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
- Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear. (NA)
- Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI (PHASE3)
- Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadovist®/Gadavist® CI brief — competitive landscape report
- Gadovist®/Gadavist® updates RSS · CI watch RSS
- Guerbet portfolio CI